Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 14/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9938232 | 0.98 | KIF11 (0.44) | KIF11KCNH2L3MBTL1LMNAMAPT | |
| SCHEMBL6248439 | 0.85 | KIF11 (0.46) | KIF11KCNH2CYP2C19 | |
| SCHEMBL27899326 | 0.83 | KIF11 (0.44) | KIF11KCNH2L3MBTL1LMNAMAPT | |
| SCHEMBL27577126 | 0.81 | KIF11 (0.46) | KIF11KCNH2L3MBTL1LMNAMAPT | |
| SCHEMBL8035494 | 0.80 | CYP4F2 (0.51) | TDP1CYP3A4 | |
| SCHEMBL1635914 | 0.80 | HDAC3 (0.53) | KIF11L3MBTL1LMNAMAPTTDP1 | |
| SCHEMBL12504099 | 0.79 | KIF11 (0.47) | KIF11KCNH2CYP3A4CYP2C9CYP2D6 | |
| Bromide SCHEMBL9938231 | 0.78 | KIF11 (0.50) | KIF11LMNAMAPTHDAC6CYP2C19 | |
| SCHEMBL8346824 | 0.78 | KIF11 (0.47) | KIF11KCNH2CYP3A4CYP2C9PRSS1 | |
| SCHEMBL1633685 | 0.78 | KIF11 (0.53) | KIF11LMNAMAPTHDAC6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932290-B2 | Method for the treatment of metabolic disorders | WELLSTAT BIOLOGICS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2266946-A2 | Compound For The Treatment Of Metabolic Disorders | Wellstat Therapeutics Corporation (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100087541-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| EP-1618086-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7615575-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-7605181-B2 | Method for the treatment of metabolic disorders | Wellstat Therapeutics Orporation (US) | 2009-10-20 | — | — | US | disclosed |
| US-7361686-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-04-22 | — | — | US | disclosed |
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20070105955-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2007-05-10 | — | — | US | disclosed |
| EP-1618086-A4 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1601251-A4 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2006-11-02 | — | — | US | disclosed |
| EP-1618086-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1601251-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004093806-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004073611-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087541-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, CPT1A | KIF11 3125/4885KCNH2 1321/4885L3MBTL1 242/4885 |
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, CPT1A | KIF11 3125/4885KCNH2 1321/4885L3MBTL1 242/4885 |
| US-20070105955-A1 | Compounds for the treatment of metabolic disorders | CPT1B, FABP1, CPT1A | KIF11 3525/4885KCNH2 1119/4885L3MBTL1 228/4885 |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | CPT1B, CPT1A, FABP1 | KIF11 2276/4885KCNH2 1979/4885L3MBTL1 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.